Delaying Oral Anticoagulants: A False Economy?

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2024 Aug 2

PMID 39093501

Authors

Brendan Collins

Gregory Y H Lip

Affiliations

Soon will be listed here.

References

Burdett P, Lip G . Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes. 2020; 8(2):187-194. DOI: 10.1093/ehjqcco/qcaa093. View

Mulholland R, Ciminata G, Quinn T, Pollock K, Lister S, Geue C . Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation. Pharmacoeconomics. 2024; 42(11):1241-1253. PMC: 11499361. DOI: 10.1007/s40273-024-01419-2. View

Burdett P, Lip G . Targeted vs. full population screening costs for incident atrial fibrillation and AF-related stroke for a healthy population aged 65 years in the United Kingdom. Eur Heart J Qual Care Clin Outcomes. 2022; 8(8):892-898. PMC: 9670327. DOI: 10.1093/ehjqcco/qcac005. View

Buja A, Rebba V, Montecchio L, Renzo G, Baldo V, Cocchio S . The Cost of Atrial Fibrillation: A Systematic Review. Value Health. 2024; 27(4):527-541. DOI: 10.1016/j.jval.2023.12.015. View

Cookson R, Griffin S, Norheim O, Culyer A, Chalkidou K . Distributional Cost-Effectiveness Analysis Comes of Age. Value Health. 2021; 24(1):118-120. PMC: 7813213. DOI: 10.1016/j.jval.2020.10.001. View

Romiti G, Corica B, Mei D, Frost F, Bisson A, Boriani G . Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry. Europace. 2024; 26(1). PMC: 10825625. DOI: 10.1093/europace/euae021. View

Kang D, Yang P, Kim D, Jang E, Yu H, Kim T . Racial Differences in Ischemic and Hemorrhagic Stroke: An Ecological Epidemiological Study. Thromb Haemost. 2024; 124(9):883-892. DOI: 10.1055/a-2278-8769. View

Lee S, Choi E, Park S, Lee S, Han K, Oh S . Clustering of Unhealthy Lifestyle and the Risk of Adverse Events in Patients With Atrial Fibrillation. Front Cardiovasc Med. 2022; 9:885016. PMC: 9289142. DOI: 10.3389/fcvm.2022.885016. View

Huang K, Jia J, Liang F, Li J, Niu X, Yang X . Fine Particulate Matter Exposure, Genetic Susceptibility, and the Risk of Incident Stroke: A Prospective Cohort Study. Stroke. 2023; 55(1):92-100. PMC: 11831602. DOI: 10.1161/STROKEAHA.123.043812. View

10.

Romiti G, Proietti M, Bonini N, Ding W, Boriani G, Huisman M . Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022; 122(12):2030-2041. DOI: 10.1055/s-0042-1756355. View

11.

Krittayaphong R, Treewaree S, Wongtheptien W, Kaewkumdee P, Lip G . Clinical phenotype classification to predict risk and optimize the management of patients with atrial fibrillation using the Atrial Fibrillation Better Care (ABC) pathway: a report from the COOL-AF registry. QJM. 2023; 117(1):16-23. DOI: 10.1093/qjmed/hcad219. View

12.

Pokorney S, Piccini J, Stevens S, Patel M, Pieper K, Halperin J . Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc. 2016; 5(3):e002197. PMC: 4943233. DOI: 10.1161/JAHA.115.002197. View

13.

Treewaree S, Lip G, Krittayaphong R . Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry. Thromb Haemost. 2023; 124(1):69-79. DOI: 10.1055/s-0043-1772773. View

14.

Johnsen S, Proietti M, Maggioni A, Lip G . A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur Heart J. 2022; 43(31):2916-2918. DOI: 10.1093/eurheartj/ehac265. View